- $234.07m
- -$84.67m
- $9.00m
Weight-loss drug developer Metsera raises $275 million in US IPO (updated)
Weight-loss drug developer Metsera raises $275 million in US IPO
Brief: Bioage Labs Announces Company Updates On APJ, NLRP3, And Platform Programs
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO (updated)
Weight-loss drug developer Metsera reveals wider loss in US IPO filing (updated)
U.S. STOCKS ON THE MOVE-BioAge Labs, Expedia, Citizens Financial Group
U.S. STOCKS ON THE MOVE-American Battery Technology, Ollie's Bargain Outlet, BioAge Labs
BioAge Labs rises on Novartis collaboration for age-related disease drugs
Brief: Bioage Labs Announces Multi-Year Collaboration With Novartis To Discover Novel Targets For Therapies That Address Age-Related Diseases And Conditions
U.S. STOCKS ON THE MOVE-Apollo, Hershey, RH
U.S. STOCKS ON THE MOVE-Warner Bros, Seres Therapeutics, Enterprise Bancorp
Jefferies cuts PT on BioAge after obesity drug trial halted
U.S. STOCKS ON THE MOVE-Tesla, Nvidia, Palantir
U.S. STOCKS ON THE MOVE-Reddit, Dow, Macy's
Jefferies cuts PT on BioAge after obesity drug trial halted
BioAge Labs tumbles on scrapping mid-stage trial of experimental obesity drug
BioAge discontinues mid-stage trial of obesity drug (updated)
BioAge discontinues mid-stage trial of obesity drug
Brief: Bioage Labs Announces Discontinuation Of Strides Phase 2 Clinical Trial